Biotechnology

Unity Biotechnology

Mizuho Downgrades Union Biotechnology Stock Rating

Unity Biotechnology released FY2025 Q1 earnings on April 22 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4328 (forecast USD -0.4)

United Biotechnology Reports Q1 Operating Expenses of $6.891 Million

Unity Biotechnology to Host Virtual Investor Event on March 24, 2025, Discussing Clinical Study Data of UBX1325

Unity Biotechnology released FY2024 Q4 earnings on March 7 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -0.5006 USD (forecast -0.36 USD)

Unity Biotechnology released FY2024 Annual Earnings on March 7 (EST), actual revenue 0 USD (forecast 0 USD), actual EPS -1.5445 USD (forecast -1.41 USD)

Unity Biotechnology released FY2024 Q3 earnings on November 4, 2024 (EST), with actual EPS of -0.3846 (forecast -0.4)

Unity Biotechnology released FY2024 9 Months Earnings on November 4, 2024 (EST), with actual revenue of 0 and EPS of -1.0435

Unity Biotechnology released FY2023 Q4 earnings on April 15, 2024 (EST), with actual revenue of 0 USD (forecast 0 USD) and actual EPS of -0.2756 USD (forecast -0.77 USD)

Unity Biotechnology released its Q3 2023 earnings on November 13, 2023 (EST), with revenue of 0 and EPS of -2.4528

EKSO Bionics

Antelope Enterprise

Aimei Health Tech

Profusa

Delixy

Urgently

Jyong Biotech

Cemtrex

CID Holdco

ON24

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap

Unity Biotechnology(UBX.US)